Navigation Links
Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
Date:4/7/2008

BERKELEY HEIGHTS, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound will be featured at the annual meeting of the American Association for Cancer Research (AACR). The meeting will be held in San Diego, CA from April 12-16, 2008. The subject matter of several abstracts, which are relevant to both the Company's ongoing randomized Phase 3 trial of Genasense in patients with advanced melanoma, and also to any subsequent regulatory filings that may ensue from that trial, include the following:

Pharmacokinetics (PK) of oblimersen in subjects with mild and moderate renal impairment. Authors: Quereshi A, et al.

Summary: Describes the PK of Genasense in patients with impaired kidney function that may be relevant for prescribers.

Poster session: Sunday, April 13, 2008; 8:00 am.

Population pharmacokinetics (PK) of dacarbazine and Genasense in adult patients with advanced melanoma. Authors: Rezai K, et al.

Summary: Describes the PK of both Genasense and dacarbazine (the chemotherapy drug given to all patients in the Phase 3 melanoma study) and how these drugs interact when co-administered in human subjects.

Poster session: Sunday, April 13, 2008; 8:00 am.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat var
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
7. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
8. FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
9. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...RNewswire-FirstCall/--Hologic,Inc.(HologicortheCom...randsupplierofpremiumdiagnostics,medicalimagingsys...careneedsofwomen,isusingtheannualmeetingoftheRadio...inChicago,November29throughDecember3,2009tohighlig...mammographyworkstationsoftware. ,, TheHologicSe...
(Date:11/25/2009)...swire/--BioTrendsResearchGroup,Inc.releasedWave1of...inamulti-phasesyndicatedmarketresearchprojecttrack...roductlaunchthroughthefirstsixmonthsofavailability...nfrom75uniqueDermatologistsandqualitativeinformati...lara,obstaclestouse,typicalpatienttypes,productper...
(Date:11/25/2009)...ov.25/PRNewswire/--AMPACFineChemicalsLLC(AFC),asub...announcedtodaythatitreceivedtheEnvironmentalRespon...EnvironmentalSummit,sponsoredbytheCaliforniaManufa...lEnvironmentalAssociation(IEA)andtheChemicalIndust...emostprestigiousawardavailablefromallthreeorganiza...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2ResMed Acquires Laboratoires Narval 5240 1ResMed Acquires Laboratoires Narval 5240 2ResMed Acquires Laboratoires Narval 5240 3New Florida Law Allows Use of Instant Drug Tests On the Job Site 5237 1New Florida Law Allows Use of Instant Drug Tests On the Job Site 5237 2BioWa Announces Second Japanese License of POTELLIGENT 28R 29 Technology to Otsuka Pharmaceutical 5234 1BioWa Announces Second Japanese License of POTELLIGENT 28R 29 Technology to Otsuka Pharmaceutical 5234 2
...onstrate Bioabsorbable Stent Is Absorbed Within Tw...to Move and Function Similar to Untreated Vessels ...e analysis published today in The Lancet , one of...SORB clinical trial demonstrated that Abbott,s bio...pment, successfully treated coronary artery diseas...
...ng study uses quantitative imaging endpoints from ...alScopics, Inc. (Nasdaq: VSCP ), a leading provi...oday announced that BioSyntech Inc., a Canadian me...eached its enrollment goal in the Canadian-Europea...device (BST-CarGel(R)) and will now focus on quant...
Other Medicine Technology:The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 2The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 3The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 4The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 5VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 3
(Date:11/27/2009)... Three new interactive anatomy education apps fro...xpand health sciences learning opportunities for i...rham, NC (Vocus) November 27, 2009 -- Modality, I...a division of Wolters Kluwer Health, today announc... apps on the App Store. Clemente’s Anatomy, ...
(Date:11/26/2009)...ov.27/PRNewswire/--ThediabetespopulationintheUnite...medicalspendingonthediseaseisprojectedtohit$336bil...shedintheDecemberissueof DiabetesCare .TheNational...voNordisk,commissionedtheanalysisbyateamfromtheUni...numberofAmericanslivingwithdiabeteswillrisefrom23....
(Date:11/26/2009)...g drug tetrathiomolybdate (TM) has been shown in s...disease, a disease caused by an overload of copper...wn. Very little, however, is known about how the d...led by Northwestern University researchers now has...l structure of TM bound to copper-loaded metalloch...
(Date:11/26/2009)... when on an emotional rollercoaster, study finds ,... Call it the fear factor meets the jubilant sports... especially those who root for the winning team --... contested match and victory was in doubt, produci...n that this Thanksgiving weekend as you,re glued t...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Center, a p...is one of a growing number of physicians who are ...s to connect with individuals who are interested i...besity. Dr. Kim is utilizing Facebook to share bef...ctice with the community. , ...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
...release chemical compounds like marijuana that can...n from severe trauma // like accidents. Scie...ounds from gun shot, or accidents causing severe d...ometime. Scientists working for University of...
...e a new discovery regarding the cells that are res... Researchers from Wake Forest University School ...ls in the thalamus area of the brain can slow the ...e protective glutamate receptors in increasing the...
...t the period of gestation has a profound effect on...een found // that although children even if born ...sk towards psychological distress in their adultho...ntly it has been unclear whether the effect of low...
...laxis are well known. Famous vaccines include the ...// mumps etc.; Therapeutic vaccines to cure a cond...ines tested in this area include the ones against ... are also developing therapeutic vaccines to treat...
...the rising incidence in births of autistic childre.../ we may be heading towards an autistic epidemic. ...e journal Current Directions in Psychological Scie... pointed out that recent changes in the Diagnostic...
...n the International Journal of Epidemiology has im...erminant of rheumatoid arthritis and other inflamm... years of life. Rheumatoid Arthritis (RA) is a chr...eral studies have shown that maternal smoking in p...
Other Medicine News:Health News:Is low birth weight related to psychological distress in adulthood? 2Health News:Understanding Chronic Infections May Help in Developing Therapeutic Vaccines 2
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: